(The Hill) – A recent analysis projects that prices for no fewer than 350 medications in the United States will escalate in 2026. This occurs even as several pharmaceutical companies commit to more competitive pricing under newly introduced policies from the Trump administration.

According to fresh insights from health care research firm 3 Axis Advisors, initially shared by Reuters, the number of medications set to experience price increases next year surpasses the tally from this year when over 250 drugs faced price hikes.

The average rate of these price increases is around 4 percent.

This forecast follows the Trump administration’s successful enforcement of the Most Favored Nation (MFN) policy, compelling over a dozen pharmaceutical companies to agree to offer products at MFN pricing — equating to the lowest prices they offer internationally — alongside providing direct-to-consumer (DTC) options.

The anticipated launch of the DTC platform, TrumpRx, is slated for early 2026.

“This represents the greatest victory for patient affordability in the history of American health care, by far,” President Trump said at an Oval Office press conference earlier this month when announcing nine additional companies had agreed to the policy.

“The pharmaceutical companies were difficult, but they also love our country,” he added. “They knew it was unfair, but they were great.”

Pharmaceutical companies entered into voluntary agreements with the White House under the threat of their products being subjected to tariffs that would cut into their bottom lines.

Several of the products projected to cost more next year are made by the companies who have agreed to Trump’s MFN policy, including Pfizer and GSK.

Reuters noted the increases projected by 3 Axis Advisors for 2026 don’t account for rebates to pharmacy benefit managers and other discounts.

The pricing deals struck between the Trump administration and drugmakers applies to the Medicaid program, with most Americans on commercial health plans. MFN pricing could have a negligible impact on Medicaid patients because the program already guarantees the lowest price offered to any commercial payer.

Analysts have been critical of Trump’s MFN policy, arguing it does little to address the root problem behind high drug costs. When analyzing the agreements, the Centre for Economic Policy Research argued that patent monopolies are the primary driver of exorbitant drug costs, something that neither the MFN pricing deals nor drug price negotiation address.